Next Article in Journal
Combined Effects of Circulating Levels of 25-Hydroxyvitamin D and Th1 and Th2 Cytokines on Breast Cancer Estrogen Receptor Status
Next Article in Special Issue
STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications
Previous Article in Journal
A Pilot Study on the Potential of RNA-Associated to Urinary Vesicles as a Suitable Non-Invasive Source for Diagnostic Purposes in Bladder Cancer
Open AccessArticle

Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance

Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Veterinaerplatz 1, Vienna 1210, Austria
Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna (MUV), Waehringer Strasse 13A, Vienna 1090, Austria
Clinical Institute of Pathology, Medical University of Vienna (MUV), Waehringer Gürtel 18-20, Vienna 1090, Austria
Department of Molecular Biology, University of Salzburg, Hellbrunnerstrasse 34, Salzburg 5020, Austria
Author to whom correspondence should be addressed.
Cancers 2014, 6(1), 193-210;
Received: 2 December 2013 / Revised: 8 January 2014 / Accepted: 16 January 2014 / Published: 27 January 2014
(This article belongs to the Special Issue STAT3 Signalling in Cancer: Friend or Foe)
PDF [764 KB, uploaded 27 January 2014]


The transcription factors and proto-oncogenes STAT3 and STAT5 are highly activated in hematological malignancies and represent promising therapeutic targets. Whereas the importance of STAT5 as tumor promoter is beyond doubt, the role of STAT3 in hematological cancers is less well understood. Both, enforced as well as attenuated expression of STAT3 were reported in hematopoietic malignancies. Recent evidence implicates STAT3 as key player for tumor immune surveillance as it both mediates the production of and response to inflammatory cytokines. Here we investigated the effects of STAT3 deletion in a BCR/ABL-induced lymphoma model, which is tightly controlled by natural killer (NK) cells in vivo. Upon STAT3 deletion tumor growth is significantly enhanced when compared to STAT3-expressing controls. The increased tumor size upon loss of STAT3 was accompanied by reduced NK cell infiltration and decreased levels of the cytokine IFN-γ and the chemokine RANTES. Upon transplantation into NK cell-deficient mice differences in lymphoma size were abolished indicating that STAT3 expression in the tumor cells controls NK cell-dependent tumor surveillance. Our findings indicate that STAT3 inhibition in lymphoma patients will impair NK cell-mediated tumor surveillance, which needs to be taken into account when testing STAT3 inhibitors in preclinical or clinical trials. View Full-Text
Keywords: STAT3; lymphoma; BCR/ABL; NK cells; tumor immune surveillance STAT3; lymphoma; BCR/ABL; NK cells; tumor immune surveillance

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Putz, E.M.; Hoelzl, M.A.; Baeck, J.; Bago-Horvath, Z.; Schuster, C.; Reichholf, B.; Kern, D.; Aberger, F.; Sexl, V.; Hoelbl-Kovacic, A. Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance. Cancers 2014, 6, 193-210.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top